{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-104395","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2024-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.367849+00:00","generated_at":"2026-05-31T06:09:59.895600+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"FibroGen terminates CFO Juan Graham and CMO Deyaa Adib as part of cost reduction plan","bullets":["CFO Juan Graham and CMO Deyaa Adib given termination notice on Aug 30, 2024.","Graham's departure date: Dec 15, 2024; Adib's departure date: Nov 1, 2024.","Terminations are part of a cost reduction plan initiated Aug 2, 2024.","Company states decisions not due to any disagreement with executives.","Both will remain through transition periods."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-104395","json":"https://secwatch.observer/filing/0000950170-24-104395.json","markdown":"https://secwatch.observer/filing/0000950170-24-104395.md","text":"https://secwatch.observer/filing/0000950170-24-104395.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017024104395/0000950170-24-104395-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017024104395/fgen-20240830.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:09:59.895600+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5b7be6eaf9","claim":"Deyaa Adib departed as Chief Medical Officer at KYNTRA BIO, INC..","evidence_excerpt":"the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017024104395/0000950170-24-104395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"provided notice of termination"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"9e1b31039d","claim":"Juan Graham departed as Chief Financial Officer at KYNTRA BIO, INC..","evidence_excerpt":"the Company provided notice of termination to two executive officers on August 30, 2024, each of whom will remain with the Company through a transition period: Juan Graham, Chief Financial Officer and Deyaa Adib, M.D., Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921299/000095017024104395/0000950170-24-104395-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"provided notice of termination"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}